Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2082374 | Drug Discovery Today: Disease Models | 2011 | 6 Pages |
Abstract
Heart failure (HF) patients have a high prevalence of disturbed sleep. Optimal pharmacological management of HF includes the use of angiotensin converting enzyme inhibitors and β-blockers, which have been associated with decreased severity of central sleep apnea, which is probably secondary to improvements in cardiac performance. There is also evidence, however, indicating that other pharmacological treatments for HF might adversely affect sleep. This brief review introduces the topic of disturbed sleep in HF and examines the extent to which its standard pharmacological management impacts sleep quality.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Jessica A. Jiménez, Barry H. Greenberg, Paul J. Mills,